Hepatitis B and C - 19/12/17
, Kathleen B. Schwarz, MD bRésumé |
Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis B, Hepatitis C, Sustained virologic response, Pegylated interferon, Direct-acting antiviral agents, Spontaneous viral clearance
Plan
| Disclosure Statement: W. Karnsakul has had a relationship with Gilead as a sponsor for an open-label, multicenter, multicohort, single-arm study to investigate the safety and efficacy of sofosbuvir plus ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection and a phase 2, open-label, multicenter, multicohort study to investigate the safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination in adolescents and children with chronic HCV-infection and a long-term follow-up registry for adolescent and pediatric subjects who received a Gilead hepatitis C virus direct-acting antiviral in chronic hepatitis C infection trials. K.B. Schwarz: Research grants from NIDDK, Gilead, BMS, and Roche; consulting for Gilead, Roche/Genentech, and Up to Date. |
Vol 64 - N° 3
P. 641-658 - juin 2017 Retour au numéro
Article précédent
- Neonatal Cholestasis
- Erin Lane, Karen F. Murray
- Nonalcoholic Fatty Liver Disease in Children : Hepatic and Extrahepatic Complications
- Praveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Valerio Nobili, Naim Alkhouri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?